Acute shift in glutamate concentrations following experimentally induced panic with cholecystokinin tetrapeptide-a 3T-MRS study in healthy subjects

Neuropsychopharmacology

Volumn 38, Issue 9, 2013, Pages 1648-1654

  Zwanzger, Peter ^a   Zavorotnyy, Maxim ^a   Gencheva, Elena ^a   Diemer, Julia ^a   Kugel, Harald ^a   Heindel, Walter ^a   Ruland, Tillmann ^a   Ohrmann, Patricia ^a   Arolt, Volker ^a   Domschke, Katharina ^a,b   Pfleiderer, Bettina ^a  

^a UNIVERSITY OF MÜNSTER   (Germany)

^b UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CREATINE; GLUTAMIC ACID; GLUTAMINE; HYDROCORTISONE; TETRAGASTRIN;

ADULT; ANTERIOR CINGULATE; ARTICLE; BRAIN LEVEL; CORRELATION ANALYSIS; HEART RATE; HUMAN; HYDROCORTISONE RELEASE; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; MALE; NEUROCHEMISTRY; PANIC; PRIORITY JOURNAL;

ADRENOCORTICOTROPIC HORMONE; ADULT; CREATINE; FUNCTIONAL NEUROIMAGING; GLUTAMIC ACID; GLUTAMINE; GYRUS CINGULI; HEART RATE; HUMANS; HYDROCORTISONE; HYPOTHALAMO-HYPOPHYSEAL SYSTEM; MALE; PANIC DISORDER; PITUITARY-ADRENAL SYSTEM; PSYCHIATRIC STATUS RATING SCALES; TETRAGASTRIN;

EID: 84880330872     PISSN: 0893133X     EISSN: 1740634X     Source Type: Journal    
DOI: 10.1038/npp.2013.61     Document Type: Article

References (59)

1. Arnold PD, MacMaster FP, Richter MA, Hanna GL, Sicard T, Burroughs E et al (2009). Glutamate receptor gene (GRIN2B) associated with reduced anterior cingulate glutamatergic concentration in pediatric obsessive-compulsive disorder. Psychiatry Res 172: 136-139.
2. Auer DP, Putz B, Kraft E, Lipinski B, Schill J, Holsboer F (2000). Reduced glutamate in the anterior cingulate cortex in depression: an in vivo proton magnetic resonance spectroscopy study. Biol Psychiatry 47: 305-313. (Pubitemid 30109243)
3. Ballenger JC, Burrows GD, DuPont RL Jr., Lesser IM, Noyes R Jr., Pecknold JC et al (1988). Alprazolam in panic disorder and agoraphobia: results from a multicenter trial. I. Efficacy in shortterm treatment. Arch Gen Psychiatry 45: 413-422.
4. Bergink V, van Megen HJ, Westenberg HG (2004). Glutamate and anxiety. Eur Neuropsychopharmacol 14: 175-183. (Pubitemid 38410952)
5. Berman RM, Cappiello A, Anand A, Oren DA, Heninger GR, Charney DS et al (2000). Antidepressant effects of ketamine in depressed patients. Biol Psychiatry 47: 351-354. (Pubitemid 30109248)
6. Blanchard MM, Mendelsohn D, Stamp JA (2009). The HR/LR model: further evidence as an animal model of sensation seeking. Neurosci Biobehav Rev 33: 1145-1154.
7. Bliss TV, Collingridge GL (1993). A synaptic model of memory: long-term potentiation in the hippocampus. Nature 361: 31-39. (Pubitemid 23020772)
8. Bradwejn J, Koszycki D (1994). Imipramine antagonism of the panicogenic effects of cholecystokinin tetrapeptide in panic disorder patients. Am J Psychiatry 151: 261-263. (Pubitemid 24053110)
9. Brann DW, Mahesh VB (1997). Excitatory amino acids: evidence for a role in the control of reproduction and anterior pituitary hormone secretion. Endocr Rev 18: 678-700. (Pubitemid 27435540)
10. Creutzfeldt OD (1983). Abgrenzung von Hirnarealen aufgrund cytoarchitektonischer Unterschiede. In: Creutzfeldt OD (eds) Cortex Cerebri. Springer: Berlin, Heidelberg, Germany; New York, USA, pp 47-57.
11. Dillon DJ, Gorman JM, Liebowitz MR, Fyer AJ, Klein DF (1987). Measurement of lactate-induced panic and anxiety. Psychiatry Res 20: 97-105. (Pubitemid 17033631)
12. Domschke K, Zwanzger P (2008). GABAergic and endocannabinoid dysfunction in anxiety-future therapeutic targets? Curr Pharm Des 14: 3508-3517.
13. Eser D, di Michele F, Zwanzger P, Pasini A, Baghai TC, Schule C et al (2005). Panic induction with cholecystokinin-tetrapeptide (CCK-4) Increases plasma concentrations of the neuroactive steroid 3alpha, 5alpha tetrahydrodeoxycorticosterone (3alpha, 5alpha-THDOC) in healthy volunteers. Neuropsychopharmacology 30: 192-195. (Pubitemid 40024413)
14. Eser D, Leicht G, Lutz J, Wenninger S, Kirsch V, Schule C et al (2009). Functional neuroanatomy of CCK-4-induced panic attacks in healthy volunteers. Hum Brain Mapp 30: 511-522.
15. Gallinat J, Kunz D, Lang UE, Neu P, Kassim N, Kienast T et al (2007). Association between cerebral glutamate and human behaviour: the sensation seeking personality trait. Neuroimage 34: 671-678. (Pubitemid 44827774)
16. Goddard AW, Mason GF, Almai A, Rothman DL, Behar KL, Petroff OA et al (2001). Reductions in occipital cortex GABA levels in panic disorder detected with 1h-magnetic resonance spectroscopy. Arch Gen Psychiatry 58: 556-561. (Pubitemid 32523735)
17. Gorman JM, Kent JM, Sullivan GM, Coplan JD (2000). Neuroanatomical hypothesis of panic disorder, revised. Am J Psychiatry 157: 493-505. (Pubitemid 30191187)
18. Grachev ID, Apkarian AV (2000). Anxiety in healthy humans is associated with orbital frontal chemistry. Mol Psychiatry 5: 482-488.
19. Hasler G, Nugent AC, Carlson PJ, Carson RE, Geraci M, Drevets WC (2008). Altered cerebral gamma-aminobutyric acid type A-benzodiazepine receptor binding in panic disorder determined by [11C]flumazenil positron emission tomography. Arch Gen Psychiatry 65: 1166-1175.
20. Hasler G, van der Veen JW, Grillon C, Drevets WC, Shen J (2010). Effect of acute psychological stress on prefrontal GABA concentration determined by proton magnetic resonance spectroscopy. Am J Psychiatry 167: 1226-1231.
21. Herman JP, Eyigor O, Ziegler DR, Jennes L (2000). Expression of ionotropic glutamate receptor subunit mRNAs in the hypothalamic paraventricular nucleus of the rat. J Comp Neurol 422: 352-362. (Pubitemid 30387667)
22. Hoerst M, Weber-Fahr W, Tunc-Skarka N, Ruf M, Bohus M, Schmahl C et al (2010). Correlation of glutamate levels in the anterior cingulate cortex with self-reported impulsivity in patients with borderline personality disorder and healthy controls. Arch Gen Psychiatry 67: 946-954.
23. Kaplan GB, Moore KA (2011). The use of cognitive enhancers in animal models of fear extinction. Pharmacol Biochem Behav 99: 217-228.
24. Kellner M, Wiedemann K, Yassouridis A, Levengood R, Guo LS, Holsboer F et al (2000). Behavioral and endocrine response to cholecystokinin tetrapeptide in patients with posttraumatic stress disorder. Biol Psychiatry 47: 107-111. (Pubitemid 30069733)
25. Kessler RC, Stang PE, Wittchen HU, Ustun TB, Roy-Burne PP, Walters EE (1998). Lifetime panic-depression comorbidity in the National Comorbidity Survey. Arch Gen Psychiatry 55: 801-808. (Pubitemid 28413042)
26. Koszycki D, Zacharko RM, Le Melledo JM, Bradwejn J (1998). Behavioral, cardiovascular, and neuroendocrine profiles following CCK-4 challenge in healthy volunteers: a comparison of panickers and nonpanickers. Depress Anxiety 8: 1-7. (Pubitemid 28413058)
27. Krystal JH, Mathew SJ, D'Souza DC, Garakani A, Gunduz-Bruce H, Charney DS (2010). Potential psychiatric applications of metabotropic glutamate receptor agonists and antagonists. CNS Drugs 24: 669-693.
28. Leicht G, Mulert C, Eser D, Sämann PG, Ertl M, Laenger A et al (2013). Benzodiazepines counteract rostral anterior cingulate cortex activation induced by cholecystokinin-tetrapeptide in humans. Biol Psychiatry 73: 337-344.
29. Maddock RJ, Casazza GA, Buonocore MH, Tanase C (2011). Vigorous exercise increases brain lactate and Glx (glutamate\+ glutamine): a dynamic 1H-MRS study. Neuroimage 57: 1324-1330.
30. Malizia AL, Cunningham VJ, Bell CJ, Liddle PF, Jones T, Nutt DJ (1998). Decreased brain GABA(A)-benzodiazepine receptor binding in panic disorder: preliminary results from a quantitative PET study. Arch Gen Psychiatry 55: 715-720. (Pubitemid 28364388)
31. Martin EI, Ressler KJ, Binder E, Nemeroff CB (2010). The neurobiology of anxiety disorders: brain imaging, genetics, and psychoneuroendocrinology. Clin Lab Med 30: 865-891.
32. Mashhoon Y, Janes AC, Jensen JE, Prescot AP, Pachas G, Renshaw PF et al (2011). Anterior cingulate proton spectroscopy glutamate levels differ as a function of smoking cessation outcome. Prog Neuropsychopharmacol Biol Psychiatry 35: 1709-1713.
33. Mathew SJ, Amiel JM, Coplan JD, Fitterling HA, Sackeim HA, Gorman JM (2005). Open-label trial of riluzole in generalized anxiety disorder. Am J Psychiatry 162: 2379-2381. (Pubitemid 41740219)
34. Nothdurfter C, Baghai TC, Schüle C, Rupprecht R (2012). Translocator protein (18 kDa) (TSPO) as a therapeutic target for anxiety and neurologic disorders. Eur Arch Psychiatry Clin Neurosci 262(Suppl 2): 107-112.
35. Otto MW, Tolin DF, Simon NM, Pearlson GD, Basden S, Meunier SA et al (2010). Efficacy of d-cycloserine for enhancing response to cognitive-behavior therapy for panic disorder. Biol Psychiatry 67: 365-370.
36. Pfleiderer B, Michael N, Erfurth A, Ohrmann P, Homann U, Wolgast M et al (2003). Effective electroconvulsive therapy reverses glutamate/glutamine deficit in the left anterior cingulum of unipolar depressed patients. Psychiatr Res Neuroimaging 122: 185-192. (Pubitemid 36412193)
37. Pfleiderer B, Ostermann J, Michael N, Heindel W (2002). Visualization of auditory habituation by fMRI. Neuroimage 17: 1705-1710. (Pubitemid 36062761)
38. Phan KL, Fitzgerald DA, Cortese BM, Seraji-Bozorgzad N, Tancer ME, Moore GJ (2005). Anterior cingulate neurochemistry in social anxiety disorder: 1H-MRS at 4 Tesla. Neuroreport 16: 183-186. (Pubitemid 40250397)
39. Pittenger C, Coric V, Banasr M, Bloch M, Krystal JH, Sanacora G (2008). Riluzole in the treatment of mood and anxiety disorders. CNS Drugs 22: 761-786.
40. Provencher SW (1993). Estimation of metabolite concentrations from localized in vivo proton NMR spectra. Magn Reson Med 30: 672-679. (Pubitemid 23360802)
41. Ressler KJ, Rothbaum BO, Tannenbaum L, Anderson P, Graap K, Zimand E et al (2004). Cognitive enhancers as adjuncts to psychotherapy: use of D-cycloserine in phobic individuals to facilitate extinction of fear. Arch Gen Psychiatry 61: 1136-1144. (Pubitemid 39463415)
42. Riaza Bermudo-Soriano C, Perez-Rodriguez MM, Vaquero-Lorenzo C, Baca-Garcia E (2011). New perspectives in glutamate and anxiety. Pharmacol Biochem Behav 100: 752-774.
43. Rogan MT, Staubli UV, LeDoux JE (1997). Fear conditioning induces associative long-term potentiation in the amygdala. Nature 390: 604-607. (Pubitemid 28016193)
44. Roy-Byrne PP, Stang P, Wittchen HU, Ustun B, Walters EE, Kessler RC (2000). Lifetime panic-depression comorbidity in the National Comorbidity Survey. Association with symptoms, impairment, course and help-seeking. Br J Psychiatry 176: 229-235. (Pubitemid 30179841)
45. Rupprecht R, Papadopoulos V, Rammes G, Baghai TC, Fan J, Akula N et al (2010). Translocator protein (18 kDa) (TSPO) as a therapeutic target for neurological and psychiatric disorders. Nat Rev Drug Discov 9: 971-988.
46. Rupprecht R, Rammes G, Eser D, Baghai TC, Schüle C, Nothdurfter C et al (2009). Translocator protein (18 kD) as target for anxiolytics without benzodiazepine-like side effects. Science 325: 490-493.
47. Salt TE, Eaton SA (1996). Functions of ionotropic and metabotropic glutamate receptors in sensory transmission in the mammalian thalamus. Prog Neurobiol 48: 55-72. (Pubitemid 26109621)
48. Sanacora G, Mason GF, Rothman DL, Behar KL, Hyder F, Petroff OA et al (1999). Reduced cortical gamma-aminobutyric acid levels in depressed patients determined by proton magnetic resonance spectroscopy. Arch Gen Psychiatry 56: 1043-1047. (Pubitemid 29526389)
49. Schunck T, Erb G, Mathis A, Gilles C, Namer IJ, Hode Y et al (2006). Functional magnetic resonance imaging characterization of CCK-4-induced panic attack and subsequent anticipatory anxiety. Neuroimage 31: 1197-1208. (Pubitemid 43851331)
50. Sheehan DV, Lecrubier Y, Harnett-Sheehan K, Janavs J, Weiller E, Bonara LI et al (1997). Reliability and validity of the MINI International Neuropsychiatric Interview (M.I.N.I.): according to the SCID-P. Eur Psychiatry 12: 232-241. (Pubitemid 27298916)
51. Shlik J, Aluoja A, Vasar V, Vasar E, Podar T, Bradwejn J (1997). Effects of citalopram treatment on behavioural, cardiovascular and neuroendocrine response to cholecystokinin tetrapeptide challenge in patients with panic disorder. J Psychiatry Neurosci 22: 332-340. (Pubitemid 28035937)
52. Strohle A, Romeo E, di Michele F, Pasini A, Hermann B, Gajewsky G et al (2003). Induced panic attacks shift gamma-aminobutyric acid type A receptor modulatory neuroactive steroid composition in patients with panic disorder: preliminary results. Arch Gen Psychiatry 60: 161-168. (Pubitemid 36173122)
53. Strohle A, Romeo E, Di Michele F, Pasini A, Yassouridis A, Holsboer F et al (2002). GABA(A) receptor-modulating neuroactive steroid composition in patients with panic disorder before and during paroxetine treatment. Am J Psychiatry 159: 145-147. (Pubitemid 41070744)
54. Stutzmann JM, Cintrat P, Laduron PM, Blanchard JC (1989). Riluzole antagonizes the anxiogenic properties of the beta-carboline FG 7142 in rats. Psychopharmacology (Berl) 99: 515-519. (Pubitemid 19273108)
55. Walker DL, Davis M (2002). The role of amygdala glutamate receptors in fear learning, fear-potentiated startle, and extinction. Pharmacol Biochem Behav 71: 379-392. (Pubitemid 34117707)
56. White KS, Barlow DH (2002). Panic disorder and agoraphobia. In: Barlow DH (eds) Anxiety and its Disorders. The Guilford Press: New York, London, UK, pp 328-379.
57. Zwanzger P, Domschke K, Bradwejn J (2012). Neuronal network of panic disorder: the role of the neuropeptide cholecystokinin. Depress Anxiety 29: 762-774.
58. Zwanzger P, Eser D, Aicher S, Schule C, Baghai TC, Padberg F et al (2003). Effects of alprazolam on cholecystokinin-tetrapeptideinduced panic and hypothalamic-pituitary-adrenal-axis activity: a placebo-controlled study. Neuropsychopharmacology 28: 979-984.
59. Zwanzger P, Rupprecht R (2005). Selective GABAergic treatment for panic? Investigations in experimental panic induction and panic disorder. J Psychiatry Neurosci 30: 167-175. (Pubitemid 40942455)